Dongbang Medical is a domestic filler company that has secured NMPA approval in China, the fifth such company in Korea, based on 40 years of expertise, and is actively targeting overseas markets through the Elasty brand.
In particular, it is accelerating its entry into the Chinese market through a partnership with Shinyang, the largest cosmetic surgery app in China, and is actively engaging in various countries, including Indonesia and the United States, by participating in academic conferences and seminars.
However, it remains uncertain how many resources Shinyang will allocate to Dongbang Medical, and it will be necessary to observe how Shinyang's traffic and marketing resources will contribute to Dongbang Medical's growth.
Dongbang Medical's Growth is Unremarkable
I'm very interested in the Chinese filler market these days.
I discovered Dongbang Medical, a company that is experiencing solid growth and actively running overseas academic conferences.
Dongbang Medical's Global Medical Aesthetic Brand
Elasty (ELASTY)
Financial statements have been good recently, with continuous revenue growth for the past three years.
-It has 40 years of expertise and has obtained KFDA, CE certification, and NMPA through KGMP and CGMP.
-Dongbang Medical is said to be the fifth domestic filler in Korea to enter the Chinese market through NMPA approval. Mainly exosomes and functional skin boosters.
Active activities such as seminars and academic conferences until recently
A vibrant company that is actively involved!
Overseas diversification and activation in Indonesia, the USA, China, Korea, Vietnam, Malaysia, Indonesia, and Turkey, etc.
*Participated in the 2023 IACDPB International Academic Conference in Indonesia. The 2023 IACPB was attended by 34 major companies, including Indonesia, Hong Kong, Korea, Switzerland, China, Italy, Taiwan, and Japan.
USA California X-Class Summit PDO approval completed, PCI approval pending.
Elasty Filler Global Seminar in Beijing, China
Participated in the 5th Korean Lifting Research Society 2023 (Hugel, Hansbiomed, Apromideon, Jetema, DNC, SCBIO, etc. participated)
To add my personal opinion,
The US distributor is Beneve, and
the Chinese distributor is said to be the famous Xinyang.
Company Name: Xinyangkeji 新氧科技
(NASDAQ: SY)
-The world's first listed plastic surgery platform listed on the NASDAQ in 19Y.
China's largest plastic surgery app with over 25 million members.
An app like Korea's Barbie Talk. (Meituan, Dazhong Dianping (Medical Beauty), Gengmei, etc., exist in China)
Xinyang CEO Kim Sung is a young CEO born in 1980, a Joseonjok from Heilongjiang, China.
Xinyang also has a Korean branch office.
https://www.soyoung.com/
*Reference: JM Penguin Company has been selected as the exclusive agency for Xinyang, so it seems that Korean plastic surgery clinics, dermatology clinics, or aesthetic representatives should contact "JM Penguin Company" or Xinyang's new business Korean office!
For your information, Dongbang Medical's self-developed hyaluronic acid filler 'Elasty' is exclusively sold by Xinyang.
Personal Opinion
Xinyang is the general distributor, which has the largest plastic surgery app platform in China, but I'm personally not sure if that will be a big advantage. I believe they have the authority to drive traffic and marketing resources, but I wonder if they will be able to devote a significant portion of the company's resources to Dongbang Medical.
Since Xinyang app is China's largest plastic surgery app,
it is said that the Xinyang Awards Ceremony is held every year, like the Oscars.
I'm really looking forward to this year's event.
[2023 6th Xinyang Asia-Pacific Medical Beauty Industry Awards Ceremony]
